Signal Genetics Inc (NASDAQ:SGNL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company’s flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York. “
Separately, Rodman & Renshaw set a $4.00 price target on Signal Genetics and gave the stock a “buy” rating in a report on Sunday, August 21st.
Signal Genetics (NASDAQ:SGNL) opened at 0.50 on Wednesday. Signal Genetics has a one year low of $0.40 and a one year high of $1.24. The firm’s market cap is $5.40 million. The stock’s 50 day moving average is $0.50 and its 200 day moving average is $0.52.
Signal Genetics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Signal Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.